

This first-in-category Intrasaccular Device to be used as acute and long-term solution,  
For both bifurcation and sidewall aneurysms

### PROBLEM

Long term efficacy in  
treating cerebral aneurysms




1 of 20 Americans suffer from cerebral aneurysms, local weakening of the wall of a blood vessel in the brain that is life threatening

Wide Neck Aneurysms, comprise 40% of all cases, and are known as most difficult to treat. Current technologies suffer from insufficient efficacy and unfavorable risk-benefit ratio. 50% of procedures are considered incomplete and require re-treatment or life-time follow up. Devices involve long, complex and high-risk implantation procedures, mainly due to a challenging device size choice (over 44 available configurations to select from), device structure related risks (e.g., protrusion to parent artery) and positioning inaccuracy - all contribute to the challenging statistics presented above.

### SOLUTION

LuSeed's "One-and-Done"  
Intrasaccular Device



LuSeed's device is designed to for ease of use, implantation safety, acute treatment and long-term stability via a unique device design.

LuSeed's device is placed inside the aneurysm and provides an immediate blockage of unwanted blood flow into the aneurysm sac via a dense mesh formation. The device's unique structure allows easy and intuitive implantation from various angles, which can be used uniquely for sidewall aneurysms - a category so far not relevant for intrasaccular devices and covers 30% of devices' market. The device is intended to treat both ruptured and unruptured cases, with no significant presence at the parent artery - mitigating unwanted usage of anticoagulants.

### LuSeed's advantages are:

Acute and long-term efficacy for wide neck aneurysm treatment


Feasible for Sidewall Aneurysms - A novel intrasaccular market

Agnostic to direction of implantation  
Easy and accurate deployment  
Reduced procedure time & complexity;  
5 device sizes only;

Concealed implant release mechanism eliminating protrusion to adjacent artery

Short learning curve

### TOP MILESTONES 2022



First in Human intended for Q4 2022

SAFE Round - 2.5M\$ - closing concluded. Granted IIA Grants for cumulative 1.4M\$

Chronic animal studies feature long term safety and efficacy

1<sup>st</sup> patent application - Granted US

### Market Size Huge and Growing

The global Market for Interventional treatment of cerebral aneurysms is a strong, lucrative market on the rise - projected to grow from \$1B to \$3.15 in 2027 with CAGR of 14.4%. The competitive segment of coiling is the dominant paradigm, yet due to its shortcomings, the market is ripe for its gradual replacement with intrasaccular innovation.

### MANAGEMENT TEAM

Co-founders: COO Amir Arthur & CEO Nitzan Hirsh are seasoned medical device executives, with vast experience in developing interventional multidisciplinary systems in startups. LuSeed's board features Prof. Elazer Edelman, head of MIT & Harvard Biomedical Engineering Labs, as well as Teva & Phillips VC (Sanara), Gandyr, and additional high profile investor representatives.



### COMPANY PROFILE

SEED FUNDED 2020

LOCATION  
Petach Tiwka, Israel

INDUSTRY  
Neurovascular

STATUS  
Pre-Series A